DANELLE GIAMMARCO: Open Payments
NPI 1891202065 · COLUMBUS, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$979 in 84 payments from 11 companies in 2025. Trend: 2023 $1,362 · 2024 $510 · 2025 $979
Food & beverage: $979
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $182 |
| E.R. Squibb & Sons, L.L.C. | 13 | $179 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $154 |
| Alkermes, Inc. | 11 | $141 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| Janssen Pharmaceuticals, Inc | 4 | $63 |
| Neurocrine BioSciences, Inc. | 3 | $56 |
| Axsome Therapeutics, Inc. | 2 | $54 |
| Luye Pharma (USA) Ltd. | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
Products named: VRAYLAR, COBENFY, CAPLYTA, ARISTADA, INVEGA SUSTENNA, INGREZZA, ABILIFY ASIMTUFII, Auvelity.
Industry payments across OH — which companies pay providers there.
